Efficacy and Safety of Filgrastim and Its Biosimilars to Prevent Febrile Neutropenia in Cancer Patients: A Prospective Study and Meta-Analysis

Efficacy and Safety of Filgrastim and Its Biosimilars to Prevent Febrile Neutropenia in Cancer Patients: A Prospective Study and Meta-Analysis

<b>Background</b>: The aim of this review and meta-analysis was to identify, assess, meta-analyze and summarize the comparative effectiveness and safety of filgrastim in head-to-head trials with placebo/no treatment, pegfilgrastim (and biosimilar filgrastim to update advances in the fiel...

Full description

Bibliographic Details
Main Authors:	Shruti Rastogi, Vivekananda Kalaiselvan, Sher Ali, Ajaz Ahmad, Sameer Ahmad Guru, Maryam Sarwat
Format:	Article
Language:	English
Published:	MDPI AG 2021-10-01
Series:	Biology
Subjects:	filgrastim pegfilgrastim meta-analysis granulocyte-colony stimulating factors febrile neutropenia systematic literature review
Online Access:	https://www.mdpi.com/2079-7737/10/10/1069

Similar Items

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
by: Schwartzberg LS, et al.
Published: (2018-09-01)

Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review
by: Girma Tekle Gebremariam, et al.
Published: (2022-12-01)

Lipegfilgrastim in patients with chemotherapy-induced neutropenia
by: G. D. Petrova, et al.
Published: (2015-12-01)

Biosimilars in the management of neutropenia: focus on filgrastim
by: Caselli D, et al.
Published: (2016-02-01)

Mecapegfilgrastim for prophylaxis of febrile neutropenia in children and adolescents with rhabdomyosarcoma or Ewing sarcoma: a prospective, single-arm, pilot study
by: Wen Zhao, et al.
Published: (2024-08-01)

G-CSF filgrastim biosimilar-Sandoz reduces the incidence of febrile neutropenia in patients receiving chemotherapy regimens with rest periods not exceeding 14 days: A French, multicenter, prospective, non-interventional study
by: Jean-Marc Phelip, et al.
Published: (2023-01-01)

Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study
by: Derek Weycker, et al.
Published: (2019-08-01)

Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
by: Guariglia R, et al.
Published: (2016-01-01)

Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study)
by: Henri Roché, et al.
Published: (2018-11-01)

Safety and tolerability of Peg-grafeel™, a pegfilgrastim, for the prophylactic treatment of chemotherapy-induced neutropenia and febrile neutropenia: A prospective, observational, postmarketing surveillance study in India
by: Vineet Talwar, et al.
Published: (2017-01-01)

Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia
by: Otremba B, et al.
Published: (2018-10-01)

Comparative Study of Adverse Drug Reactions Associated with Filgrastim and Pegfilgrastim Using the EudraVigilance Database
by: Shruti Rastogi, et al.
Published: (2022-02-01)

Prevention of neutropenia as an important factor in successful chemotherapy for head and neck cancer
by: L. G. Babicheva, et al.
Published: (2021-11-01)

Granulocyte colony-stimulating factor usage in drug-induced neutropenia after kidney transplantation: a single-center experience
by: Emel Isiktas Sayilar, et al.
Published: (2020-01-01)

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey
by: Innocenti R, et al.
Published: (2018-12-01)

Quantification of the cellular content of platelet-rich plasma harvested after injection of filgrastim versus pegfilgrastim biosimilars: a prospective, single-center, crossover study
by: Mohammadreza Abbasian, et al.
Published: (2024-12-01)

Pegfilgrastim on febrile neutropenia in pediatric and adolescent cancer patients: a systematic review and meta-analysis
by: Xia Zhu, et al.
Published: (2023-12-01)

Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim
by: Ka‐Won Kang, et al.
Published: (2020-09-01)

Factors Associated with Absolute Neutrophil Count Dynamics and Docetaxel-Adryamicin-Cyclophosphamide (TAC) Chemotherapy Induced Neutropenia During Extended Filgrastim Administration in Breast Cancer Patients
by: Ami Ashariati, et al.
Published: (2022-07-01)

Budget Saving Potential of Pegfilgrastim Biosimilar for the Treatment of Chemotherapy-Induced Febrile Neutropenia, in Italy
by: Patrizia Berto, et al.
Published: (2022-02-01)

Recurrence of Large-Vessel Vasculitis Induced by Multiple Types of Granulocyte Colony-Stimulating Factor Preparation in Patient with Large-Cell Neuroendocrine Lung Carcinoma: A Case Report
by: Yurie Seto, et al.
Published: (2023-09-01)

Chemotherapy limiting neutropenia. Is prevention required?
by: I. B. Kononenko, et al.
Published: (2022-01-01)

Prevention of neutropenia during chemotherapy by prolonged myelostimulatory preparations
by: V. V. Ptushkin, et al.
Published: (2015-06-01)

Prevention of neutropenia during chemotherapy by prolonged myelostimulatory preparations
by: V. V. Ptushkin, et al.
Published: (2015-06-01)

New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim
by: Ghidini M, et al.
Published: (2016-06-01)

A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients
by: Roberto Hegg, et al.

Health professionals’ preferences with the use of pegfilgrastim on-body injector at oncology centers in 8 cities in Colombia
by: María Alejandra Larrarte-González, et al.
Published: (2023-05-01)

Efficacy of filgrastim and Lenograstim drug treatment in patients with neutropenia: a systematic review
by: Sogol Shirzad, et al.
Published: (2023-10-01)

Comparing the efficacy and side-effects of PDLASTA® (Pegfilgrastim) with PDGRASTIM® (Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial
by: Safa Najafi, et al.
Published: (2021-04-01)

Role of biosimilars in neutropenia prevention in cancer patients
by: V. V. Ptushkin
Published: (2015-01-01)

Role of biosimilars in neutropenia prevention in cancer patients
by: V. V. Ptushkin
Published: (2015-01-01)

Clozapine-Induced Febrile Neutropenia and Cellulitis
by: Selcuk YAYLACI, et al.
Published: (2014-03-01)

Study of PEG-Filstim sub-acute toxicity
by: V. L. Karbovskyi, et al.
Published: (2018-08-01)

Anaphylaxis from filgrastim prophylaxis within the same day of chemotherapy: A case report
by: Suluck Soontaros, et al.
Published: (2024-12-01)

Use of prophylactic pegfilgrastim for chemotherapy-induced neutropenia in the US: A review of adherence to present guidelines for usage
by: Jeffrey Crawford, et al.
Published: (2021-01-01)

Efficacy and safety of pegfilgrastim biosimilar MD‐110 in patients with breast cancer receiving chemotherapy: Single‐arm phase III
by: Toshimi Takano, et al.
Published: (2023-10-01)

The Prognostic Utility of Lymphocyte-Based Measures and Ratios in Chemotherapy-Induced Febrile Neutropenia Patients following Granulocyte Colony-Stimulating Factor Therapy
by: Omar M. Halalsheh, et al.
Published: (2022-10-01)

Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety
by: Reshma Mahtani, et al.
Published: (2021-05-01)

Prophylaxis against febrile neutropenia with pegfilgrastim in Italy: a budget impact analysis
by: Giovanni Rosti, et al.
Published: (2011-09-01)

Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051
by: Keita Miura, et al.
Published: (2024-02-01)